On this page
If you stop a GLP-1, your appetite comes back, and for most people a large share of the lost weight comes back with it. The drug didn’t fail, and your willpower didn’t break. Obesity is a chronic condition that tends to relapse, so this is the predictable result of stopping an ongoing treatment, and the withdrawal trials show it plainly.
What the trials found when people stopped
The clearest number comes from SURMOUNT-4 (Aronne et al., JAMA 2024). Everyone first took brand-name tirzepatide (Zepbound) for several months and worked up to a full maintenance dose. Then they were randomly split, so some kept taking it for the next year and some switched to placebo. The group that kept going lost another 5.5% of their body weight, while the group that stopped regained about 14%. Both groups got there the same way, and the only difference afterward was whether they stayed on the drug.
Semaglutide works the same way. In STEP 4 (Rubino et al., JAMA 2021), people who had already lost weight over 20 weeks on brand-name semaglutide (Wegovy) were split into two groups: keep going, or switch to placebo. Those who kept going kept losing, and those who stopped regained a large share of what they’d lost.
The design is what makes these trials convincing. Both used a run-in period, where everyone took the drug first, and only people who were actually on it were then randomly assigned to keep going or stop. So you can’t explain away the regain by saying the drug never worked for them. It worked, they lost weight, and taking the drug away undid it. That’s about as close to a controlled test of stopping as the research has.
The people who stopped the drug didn’t quit the program. They stayed on a structured weight plan with ongoing diet and exercise coaching, and they still regained the weight. Lifestyle support is worth having. But on its own, it isn’t what kept the weight off.
One caution: these are group averages, and people vary. An average regain of 14% doesn’t mean everyone goes all the way back to their starting weight, since some keep more of the loss and some keep less. But the trend is steady enough that any plan should treat regain as the default to work against.
To see how much is at stake: in STEP 1 (Wilding et al., NEJM 2021), people on brand-name semaglutide (Wegovy) lost 14.9% on average at 68 weeks. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), people on brand-name tirzepatide (Zepbound) lost 15% to 20.9%, depending on dose. We go deeper on why the weight bounces back in rebound weight after a GLP-1.
The weight comes back because the biology does
A GLP-1 only works while it’s in your body. These drugs slow gastric emptying (how fast your stomach empties), act on the appetite centers in your brain, and help your body release insulin when your blood sugar rises. Tirzepatide also works on a second receptor, called GIP.
None of that permanently resets your body’s appetite set-point. When the drug clears, the signals it was holding down switch back on, and your body goes back to defending the higher weight it came from. Food noise and hunger return, you eat more, and your weight follows.
Weight loss also makes your body burn a bit less energy overall, which is a well-known part of obesity physiology, and that adds to the appetite rebound.
This is the same machinery behind ordinary diet rebound, because your body treats lost fat as a shortage to fix. It doesn’t know or care whether a drug or a diet caused the loss. That’s why calling regain a failure of discipline gets it wrong.
The weight comes back slowly because these drugs leave your body slowly. Semaglutide has a half-life of about a week (half the drug is gone after about seven days). Your appetite tends to climb back over the weeks after your last dose.
That delay is a trap, because some people take their first few good weeks off the drug as proof they’ve “kept” the results, right before the hunger comes back.
Here’s the honest way to see it. A GLP-1 manages a condition, but it doesn’t cure it. Semaglutide treats obesity the way a blood pressure pill treats blood pressure. It works while you take it, and the numbers drift back when you stop. We say this plainly because the other way of seeing it, as a course you finish, sets people up to blame themselves for normal biology.
Does tapering down soften the landing?
This is where the evidence runs thin fast. The withdrawal trials didn’t taper, since they stopped the drug or switched people to placebo. No trial shows that lowering the dose slowly prevents or reduces regain compared with stopping all at once. We don’t know whether a taper changes what happens.
It’s biologically plausible that easing off could soften the appetite rebound, but plausible isn’t the same as shown. Anyone selling a “taper protocol” as a proven way to keep weight off is getting ahead of the data.
It helps to split this into two questions. The first is stomach comfort, since a slower step-down may spare you the jolt of a sudden change in gastric emptying, and that’s a reasonable goal. The second is whether a taper keeps the pounds off, and no trial backs that part. A taper can make sense for the first reason and still do nothing you can measure for the second.
There’s no set taper schedule. If you and your clinician decide to step down, the pace and the check-ins are planned for you, and a taper isn’t a promise the weight will stay off.
How you did on the way up tells you something. If your appetite was still loud at 1.0 mg while your dose was going up, 1.0 mg probably won’t hold you on the way down.
Be clear about which parts are evidence and which are judgment. The comfort reason is sound and based on how the drug works. The idea that tapering protects your weight better than stopping outright has no trial behind it.
The other option is not stopping
Staying on the drug is what the trials actually support. In both STEP 4, on brand-name semaglutide (Wegovy), and SURMOUNT-4, on brand-name tirzepatide (Zepbound), the group that stayed on treatment held or extended its loss, so if keeping the weight off is your goal, staying on the medication is the option with direct trial support. That’s why how long you stay on a GLP-1 is a medical decision. It isn’t a set course with a finish line.
Staying on doesn’t have to mean staying at the top dose. Some people step down to a lower maintenance dose once they reach their goal. The catch is that the trials kept people on their full treatment dose, so the data doesn’t tell us much about how well a lower dose holds. It’s a reasonable clinical practice, but trials haven’t proven it.
The next worry is usually whether it’s safe to stay on for years. SELECT (Lincoff et al., NEJM 2023) followed 17,604 people for an average of more than three years, making it the largest long-term safety dataset we have, and brand-name semaglutide (Wegovy) lowered major heart events by 20% (hazard ratio 0.80). So far, people handle long-term treatment well. That doesn’t answer every question. But it’s a reason not to quit just because “I’ve been on it a while.”
No study has set a lowest dose that works for maintenance. And “I’ve been on this a while” isn’t a reason on its own to go lower. The reason to step down is that a lower dose still holds you. You find that out by trying it with a clinician watching. Don’t just assume it.
If you’re stopping anyway, do it on a plan
People stop for good reasons: side effects that never settle, a planned pregnancy (GLP-1s are not for use in pregnancy), losing access to the drug, or simply wanting to test how their own appetite holds up without it.
Stopping is a fair choice. Stopping by accident isn’t a plan. The difference is mostly being ready: knowing what’s coming and deciding ahead of time how you’ll handle it. If you’re coming off, build these in:
- Protect your muscle. DXA body-composition scans show that a real share of GLP-1 weight loss is lean mass. Do strength training at least twice a week and keep your protein up, at a target your clinician helps you set, before, during, and after you come off, so more of the weight you keep is muscle. We don’t know yet what that lean-mass loss means long term, which is why you guard against it instead of waiting to see.
- Expect your appetite back within weeks. Set up your meals and your kitchen for hunger coming back. Don’t plan around the quiet appetite of your last few weeks on the drug.
- Agree on a follow-up plan, ahead of time. Set with your clinician when you’ll check back in, and what change would prompt a talk about restarting or other care. Write it down now, before the ups and downs of the daily scale get to you. Ongoing care may still be needed after you stop.
- Time it right around pregnancy. If you’re stopping to get pregnant, your clinician will tell you how far ahead of trying to come off.
- Keep the door open. Restarting is common. It isn’t a failure in any moral sense. If you’re looking at your options again, the five-minute quiz sends you back to a clinician who can work from your history.
What we still don’t know
The open question isn’t whether stopping leads to regain. The trials settle that. It’s whether anything softens the landing. No trial has compared stopping all at once, a planned taper, and a set low maintenance dose to see which keeps weight off longest. Until someone runs it, the answer to “how do I come off and keep the most weight?” comes from how the drug works and from clinical experience. That gap is one thing to watch, and the other is what the lost lean mass means for your body over the long run, which we still don’t know.
